Scienture Holdings SCNX
NASDAQ SCNX
$0.37 +0.01 (+1.66%)
At close: Sep 9, 2026 · 4:00 PM EDT

Scienture Holdings (SCNX) Raw Materials (2022 - 2023)

Scienture Holdings' (SCNX) quarterly Raw Materials came in at $1.9 million in Q3 2023, up 2669.12% quarter-over-quarter from $68448.0 in Q4 2022.

Analysis

Scienture Holdings (SCNX) Raw Materials (2022 - 2023) Analysis & Trends

Scienture Holdings has disclosed Raw Materials across 2 years of filings, most recently posting $1.9 million for Q3 2023.

  • In Q3 2023, Raw Materials changed N/A year-over-year to $1.9 million; the TTM figure through Sep 2023 stood at $1.9 million (changed N/A YoY), while the FY2022 annual figure was $68448.0, changed N/A from the prior year.
  • Raw Materials came in at $1.9 million for Q3 2023 at Scienture Holdings, up from $68448.0 in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $1.9 million in Q3 2023 to a low of $68448.0 in Q4 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Teva Pharmaceutical Industries 42.34 Bn 38.68 Bn 2.15 Bn
2 Viatris 19.39 Bn 18.50 Bn 1.46 Bn
3 Dr Reddys Laboratories 9.99 Bn 9.85 Bn 396.53 Mn
4 Amneal Pharmaceuticals 5.57 Bn 5.53 Bn 334.51 Mn
5 Bausch Health Companies 2.45 Bn 1.58 Bn 2.10 Bn
6 Ani Pharmaceuticals 1.70 Bn 1.34 Bn 165.89 Mn
7 Alvotech 1.66 Bn 1.52 Bn 2.56 Mn
8 Amphastar Pharmaceuticals 985.90 Mn 695.77 Mn 93.47 Mn
9 Fennec Pharmaceuticals 434.07 Mn 392.82 Mn 17.15 Mn
10 Scienture Holdings 15.19 Mn 15.19 Mn 335,779.00
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2023 1.90 Mn
Dec 31, 2022 68,448.00